Otsuka (OTCMKTS:OTSKY) Updates FY 2026 Earnings Guidance

Key Points

• Otsuka set FY2026 EPS guidance at 1.610, well below the consensus of 1.87, while providing revenue guidance of $16.1 billion, which is in line with expectations.
• The company beat quarterly estimates with EPS of $0.59 versus $0.43 expected, and the stock rose to $35.48 on above-average volume; Otsuka has a market cap of $38.11 billion and a trailing P/E of 15.43.
• Analyst sentiment is mixed after notable changes—Goldman Sachs cut its rating from "strong-buy" to "strong sell" while Morgan Stanley, UBS and Zacks issued more favorable or neutral views—leaving the consensus rating at Hold.

Otsuka (OTCMKTS:OTSKY - Get Free Report) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 1.610-1.610 for the period, compared to the consensus estimate of 1.870. The company issued revenue guidance of $16.1 billion-$16.1 billion, compared to the consensus revenue estimate of $16.1 billion.

Otsuka Stock Performance

OTSKY traded up $2.28 during midday trading on Tuesday, hitting $35.48. 61,900 shares of the company traded hands, compared to its average volume of 37,900. The company's 50-day moving average is $33.87 and its 200 day moving average is $30.49. The company has a quick ratio of 1.67, a current ratio of 2.17 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $38.11 billion and a PE ratio of 15.43. Otsuka has a 52 week low of $21.64 and a 52 week high of $36.55.

Otsuka (OTCMKTS:OTSKY - Get Free Report) last released its quarterly earnings data on Tuesday, April 28th. The company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.16. Otsuka had a net margin of 14.76% and a return on equity of 12.52%. Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. On average, research analysts expect that Otsuka will post 1.87 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. The Goldman Sachs Group lowered shares of Otsuka from a "strong-buy" rating to a "strong sell" rating in a research note on Friday, February 27th. Morgan Stanley raised Otsuka to an "overweight" rating in a report on Friday, January 23rd. UBS Group raised Otsuka to a "hold" rating in a report on Tuesday, January 27th. Finally, Zacks Research raised Otsuka from a "strong sell" rating to a "hold" rating in a research report on Tuesday, March 31st. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Otsuka currently has an average rating of "Hold".

About Otsuka

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm's core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.